Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
News
The Alzheimer's drug pipeline is shifting its gaze from amyloid to tau. A new TD Cowen analysis highlights growing physician enthusiasm for tau-targeting therapies, with a potential market worth up to $70 billion by 2035. A Biogen tau therapy recently showed promising results in slowing cognitive decline — but FDA approval, safety questions, and insurance coverage remain key hurdles.
The Alzheimer's drug landscape is evolving fast. While billions have already been poured into amyloid-targeting therapies — with drugs like Leqembi and Kisunla showing modest benefits but notable safety risks — researchers and clinicians are now zeroing in on tau, a protein that clumps abnormally in Alzheimer's and frontotemporal dementia. A proprietary TD Cowen analysis finds surging excitement around tau-targeting treatments, with 88% of surveyed physicians saying they'd likely use an effective tau therapy that requires less safety monitoring than current options.
In a notable milestone, a Biogen tau-targeting therapy showed it could slow cognitive decline in early Alzheimer's patients with only mild-to-moderate side effects — earning cautious optimism from the Alzheimer's Association. Researchers also envision future combination therapies pairing amyloid-clearing drugs with tau suppressants and anti-inflammatory agents, mirroring cancer treatment models.
By the Numbers:
Why it matters: No tau therapies are FDA-approved yet, and questions around dosing, blood-brain barrier delivery, and insurance coverage loom large. But if these drugs deliver, they could represent a meaningful leap forward for millions of patients — and reshape the entire Alzheimer's treatment market.
